Commentary to Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction

High Blood Press Cardiovasc Prev. 2021 Jul;28(4):331-332. doi: 10.1007/s40292-021-00455-9. Epub 2021 Apr 27.

Authors

Agata Buonacera¹, Benedetta Stancanelli¹, Lorenzo Malatino²

Affiliations

¹ Academic Unit of Internal Medicine and Hypertension Centre, Department of Clinical and Experimental Medicine, University of Catania, c/o Cannizzaro Hospital, Via Messina 829, 95126, Catania, Italy.
² Academic Unit of Internal Medicine and Hypertension Centre, Department of Clinical and Experimental Medicine, University of Catania, c/o Cannizzaro Hospital, Via Messina 829, 95126, Catania, Italy. malatino@unict.it.

PMID: 33905096
DOI: 10.1007/s40292-021-00455-9

No abstract available

Publication types

Letter
Comment

MeSH terms

Aminobutyrates* / adverse effects
Biphenyl Compounds
Drug Combinations
Heart Failure* / diagnosis
Heart Failure* / drug therapy
Humans
Stroke Volume
Tetrazoles / adverse effects
Valsartan

Substances

Aminobutyrates
Biphenyl Compounds
Drug Combinations
Tetrazoles
Valsartan
sacubitril and valsartan sodium hydrate drug combination